Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146
Chung‐Han Lee,Amishi Y. Shah,Arpit Rao,Matthew H. Taylor,Christopher Di Simone,James J. Hsieh,Álvaro Pinto,Regina Gironés Sarrió,Allen Lee Cohn,Mehmet Asım Bilen,Sara Gunnestad Ribe,Øyvind Tennøe,Donald Richards,Randy F. Sweis,Jay Courtright,Daniel Heinrich,Rodolfo F. Perini,Peter Kubiak,Daena Bock,Chinyere E. Okpara,Robert J. Motzer